Interpace Biosciences, Inc. (OTCMKTS:IDXG – Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 785 shares, an increase of 7,750.0% from the May 31st total of 10 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 11,418 shares, the short-interest ratio is presently 0.1 days.
Interpace Biosciences Stock Performance
Interpace Biosciences stock traded down $0.06 during mid-day trading on Thursday, reaching $1.64. 26,686 shares of the company were exchanged, compared to its average volume of 7,976. The firm’s 50-day simple moving average is $1.83 and its two-hundred day simple moving average is $1.69. Interpace Biosciences has a twelve month low of $0.70 and a twelve month high of $2.40. The firm has a market cap of $7.27 million, a PE ratio of -32.80 and a beta of 0.59.
Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) last released its earnings results on Tuesday, May 12th. The business services provider reported $0.03 earnings per share (EPS) for the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.The business had revenue of $9.03 million for the quarter.
About Interpace Biosciences
Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.
Recommended Stories
- Five stocks we like better than Interpace Biosciences
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
